Immunoglobulin complexes in sera of patients with malignancy

Sera frour 146 patients with malignancy, 59 normal controls and 42 patients hospitalized with non-malignant diseases were examined by a precipitin test with monoclonal rheumatoid factor (mRF) for the presence of circulating immune complexes containing IgG. Forty-two (29%) of the sera from cancer patients but only two of the sera from patients in each of the control groups contained such material. Similar results were obtained with a radioimmunoassay for immune complexes based on the same mRF. Sera from 23 of 65 patients with metastatic malignancy (35%) had elevated levels of immune complexes by this latter test. The presence of the material was not related to the source of malignancy, presence of carcinoembryonic or hepatitis antigens or of such autoantibodies as rheumatoid factor or anti-DNA. By density gradient ultracentrifugation the reacting material was identified as being of molecular size 19s or greater. It has not yet been further characterized with regard to the nature of any antigens present.

The therapeutic activity, post-treatment fertility and safety of prostaglandin F2alpha-Tham salt in clinically anoestrous mares: a review

Of 275 mares receiving prostaglandin F2alpha-Tham salt for its luteolytic effect upon the corpus luteum, 231 (84 per cent) exhibited signs of oestrus (range 73-95 per cent). Some mares not exhibiting overt oestrus may, nevertheless, ovulate and post-treatment rectal palpation of mares apparently failing to respond is suggested in these cases. Of 210 mares for which subsequent history was available. 104 (49.5 per cent) became pregnant from breeding at the post-treatment oestrus that immediately followed the induced regression of the corpus luteum (range 42.2-55.5 per cent). Fertility is comparable at this oestrus to that of naturally occurring oestrus in Thoroughbred mares. Side effects with PGF2alpha-Tham are physiological responses to the prostaglandin and include various degrees of sweating, some hypermotility of the gastrointestinal tract, increased pulse and respiratory rates and, occasionally, abdominal discomfort. These signs only occur in a proportion of mares, are transitory in nature and are resolved without treatment. A brief review of a comprehensive toxicity study using 20-160 times the recommended dose level, daily for 8 days, concludes that PGF2alpha-Tham has a 20 times safety margin for a single injection.